Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-center, Double-blind, Randomized, Placebo-controlled Phase 1 Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-ascending Doses of ACT-1014-6470 in Healthy Subjects

NCT04608513 is registered in ClinicalTrials.gov with Idorsia Pharmaceuticals Ltd. as lead sponsor.

NCT NCT04608513
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04608513 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-center, Double-blind, Randomized, Placebo-controlled Phase 1 Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-ascending Doses of ACT-1014-6470 in Healthy Subjects
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Phase
Phase 1
Overall status
Completed
Start date
November 16, 2020
Completion date
September 20, 2021
Enrollment
46 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy